Cargando…

Peptides of a Feather: How Computation Is Taking Peptide Therapeutics under Its Wing

Leveraging computation in the development of peptide therapeutics has garnered increasing recognition as a valuable tool to generate novel therapeutics for disease-related targets. To this end, computation has transformed the field of peptide design through identifying novel therapeutics that exhibi...

Descripción completa

Detalles Bibliográficos
Autores principales: Kazmirchuk, Thomas David Daniel, Bradbury-Jost, Calvin, Withey, Taylor Ann, Gessese, Tadesse, Azad, Taha, Samanfar, Bahram, Dehne, Frank, Golshani, Ashkan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10298604/
https://www.ncbi.nlm.nih.gov/pubmed/37372372
http://dx.doi.org/10.3390/genes14061194
Descripción
Sumario:Leveraging computation in the development of peptide therapeutics has garnered increasing recognition as a valuable tool to generate novel therapeutics for disease-related targets. To this end, computation has transformed the field of peptide design through identifying novel therapeutics that exhibit enhanced pharmacokinetic properties and reduced toxicity. The process of in-silico peptide design involves the application of molecular docking, molecular dynamics simulations, and machine learning algorithms. Three primary approaches for peptide therapeutic design including structural-based, protein mimicry, and short motif design have been predominantly adopted. Despite the ongoing progress made in this field, there are still significant challenges pertaining to peptide design including: enhancing the accuracy of computational methods; improving the success rate of preclinical and clinical trials; and developing better strategies to predict pharmacokinetics and toxicity. In this review, we discuss past and present research pertaining to the design and development of in-silico peptide therapeutics in addition to highlighting the potential of computation and artificial intelligence in the future of disease therapeutics.